As Rituxan Biosimilar Enjoys Solid Start, Sandoz Japan Chief Says It’s Important to Be First to Market

Sandoz Japan President Jason Hoffe Being first-to-market is important in the biosimilar space, and a strong uptake seen with Sandoz’s Rituxan (rituximab) follow-on offers a good case in point, Jason Hoffe, president of the company’s Japan unit, tells Jiho. “I...read more